Patent · US Active

Biomarkers for risk assessment and treatment monitoring in heart failure patients guided by natriuretic peptides

US10684291B2 · kind B2 · utility

1Cited by

8References

10Claims

0Family size

Assignee

Roche Diagnostics Operations, Inc. · US

Inventors

Dirk Block · Bichl, DE
Hans-Peter Brunner · Münchenstein, CH
Ursula-Henrike Wienhues-Thelen · Krailling, DE
Christian Zaugg · Rheinfelden, CH
Thomas Dieterle · Freiburg (Elbe), DE
Cheryl R. Mitchell · Stockton, US
Johan Ubby · Zug, CH
Sandra Sanders-van Wijk · Eijsden, NL

Key dates

Filing date	Jul 27, 2016
Grant date	Jun 16, 2020
Priority date	—
Expiry date	Jul 27, 2036

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The present description relates to a method for identifying a patient who is eligible for an intensification of heart failure therapy. Furthermore, the description relates to a method for optimizing B type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. Further described are kits and devices adapted to carry out the described method.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.